Cell No. : Cell Name
RCB2230 : HS-Sch-2
update : 2023/01/04
|
| Comment | Human cell line derived from malignant peripheral nerve sheath tumor (MPNST). |
| Comment from the depositor | |
| Terms and conditions | There is no restriction regarding use for basic researches. In relation to commercial use and use for patent filing, first of all please contact the RIKEN BRC. |
| Remarks | |
| Order Form |
Order Form(C-0005.pdf)
MTA(C-0007.pdf)
MTA(C-0007p.pdf)
|
|
Regarding MTA between user institutions and RIKEN BRC, there are two kinds of MTA, not-for-profit academic purpose (C-XXXX) and for-profit research purpose (C-XXXXp) , depending on the sort of user institutions and the purposes of use. Please use an appropriate MTA(to see). In relation to commercial use and use for patent filing, first of all Please contact RIKEN BRC (cellbank.brc@riken.jp).
|
|
|
Basic information
|
Depositor |
Sonobe, Hiroshi
|
| Originator |
Sonobe, Hiroshi
|
| Year of deposit |
2002
|
| Animal |
human
< Mammals
|
| Genus |
Homo
|
| Species |
sapiens
|
| Gender |
Female
|
| Age at sampling |
54 years
|
| Tissue |
unknown
|
| Disease name |
malignant peripheral nerve sheath tumour (MPNST)
|
| Classification |
cancer
|
|
Lifespan |
infinite
|
| Morphology |
other
|
| Cellosaurus(Expasy) |
CVCL_8718
|
|
| |
deposit info |
lot info |
|
Medium |
Medium List |
|
Culture type |
|
Adherent cells
|
| Medium and additives |
|
DMEM (low glucose) + 10% FBS
|
| Antibiotics |
|
Free
|
|
Passage method |
|
0.25% Trypsin
|
Culture information
|
Passage ratio |
|
1 : 6-8 split
|
| SC frequency |
|
Subculture : 2 times/week
|
| Temperature |
|
37
℃
|
| CO2 concentration |
|
5
%
|
| Freeze medium |
|
Medium + 10% DMSO
|
| Freezing method |
|
Slow freezing
|
| Mycoplasma |
|
(-)
|
| Isozyme |
|
LD, NP
|
| STR(human) |
|
OK
|
| Images |
deposit info | lot info |
|
|
|
| Reference information |
Reference |
1
|
| User's Publication |
5
|
| User's Publication |
|
20170
Yamada H, Takahashi M, Watanuki M, Watanabe M, Hiraide S, Saijo K, Komine K, Ishioka C.
lncRNA HAR1B has potential to be a predictive marker for pazopanib therapy in patients with sarcoma.
Oncol Lett
2021
21(6):455
PubMed ID: 33907565
DOI: 10.3892/ol.2021.12716
|
|
16822
Terribas E, Fernández M, Mazuelas H, Fernández-Rodríguez J, Biayna J, Blanco I, Bernal G, Ramos-Oliver I, Thomas C, Guha R, Zhang X, Gel B, Romagosa C, Ferrer M, Lázaro C, Serra E.
KIF11 and KIF15 mitotic kinesins are potential therapeutic vulnerabilities for malignant peripheral nerve sheath tumors
Neurooncol Adv
2020
2(Suppl 1):i62-i7
PubMed ID: 32642733
DOI: 10.1093/noajnl/vdz061
|
|
10338
Fukushima S, Endo M, Matsumoto Y, Fukushi JI, Matsunobu T, Kawaguchi KI, Setsu N, IIda K, Yokoyama N, Nakagawa M, Yahiro K, Oda Y, Iwamoto Y, Nakashima Y.
Hypoxia-inducible factor 1 alpha is a poor prognostic factor and potential therapeutic target in malignant peripheral nerve sheath tumor.
PLoS ONE
2017
12:e0178064
PubMed ID: 28558056
DOI: 10.1371/journal.pone.0178064
|
|
14763
Kolberg M, Bruun J, Murumägi A, Mpindi JP, Bergsland CH, Høland M, Eilertsen IA, Danielsen SA, Kallioniemi O, Lothe RA.
Drug sensitivity and resistance testing identifies PLK1 inhibitors and gemcitabine as potent drugs for malignant peripheral nerve sheath tumors
Mol Oncol
2017
11(9):1156-1171
PubMed ID: 28556483
DOI: 10.1002/1878-0261.12086
|
|
9577
Tanaka T, Kikuchi N, Goto K, Iino M.
Sec6/8 regulates Bcl-2 and Mcl-1, but not Bcl-xl, in malignant peripheral nerve sheath tumor cells.
Apoptosis
2016
21:594-608
PubMed ID: 26892009
DOI: 10.1007/s10495-016-1230-9
|
Back
Top
CELL BANK Website
